Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. (October 2019)

• Record Type: Journal Article
• Authors: Minisola, Salvatore; Cipriani, Cristiana; Grotta, Giada Della; Colangelo, Luciano; Occhiuto, Marco; Biondi, Piergianni; Sonato, Chiara; Vigna, Evelina; Cilli, Mirella; Pepe, Jessica
• Is Part Of: Therapeutic advances in musculoskeletal disease. Volume 11(2019)
• Publication Date: 2019-10
• Subjects: fractures -- osteoporosis -- safety -- teriparatide; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; 616.7
• DOI: 10.1177/1759720X19877994
• Languages: English
• ISSNs: 1759-720X

Abstract

Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received additional approval for the treatment of osteoporosis in men, and for the treatment of osteoporosis associated with glucocorticoid therapy in men and women at risk of fracture. In this review, we summarize the most important data concerning PTH 1-34 therapy before 2016 in the treatment of osteoporosis, and report some outstanding results published in the last 2 years. New data on safety will also discussed, together with the state of art of nonclassical utilization. Finally, in view of the recent approval of biosimilars, possible future landscapes are discussed.